Safety Study of NHL With 90Y-hLL2 IgG
NCT00421395
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
59
Enrollment
INDUSTRY
Sponsor class
Conditions
NHL
B-cell NHL
Non-Hodgkins Lymphoma
Interventions
BIOLOGICAL:
90Y-hLL2
Sponsor
Gilead Sciences